Yi Lin MD PhD (She/Her)

Hematologic Oncology

Associate Professor, Internal Medicine, Mayo Medical School. Chair, Cell Therapy Group Mayo Clinic Cancer Center

200 1st St SWRochester, MN 55905
Phone+1 507-284-2511

Dr. Lin is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lin's full profile Already have an account?

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2007 - 2011
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2004 - 2007
Northwestern University The Feinberg School of MedicineClass of 2004

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MN State Medical License 2005 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Centricity Enterprise (CE), GE Healthcare, 2013-2017
CMS Meaningful Use Stage 2 Certification Mayo Clinic Patient Lists, Mayo Clinic, 2013-2017
CMS Meaningful Use Stage 2 Certification Mayo Clinic Electronic Notes, Mayo Clinic, 2013-2017

Publications & Presentations

PubMed

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.
Kenneth J C Lim, Shaji Kumar, Ricardo Parrondo, Saurabh Chhabra, Melinda Tan
American Journal of Hematology. 2026-09-01
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.
Daniel G Packard, Shaji K Kumar, Angela Dispenzieri, Prashant Kapoor, Guneet Janda
American Journal of Hematology. 2026-09-01
Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.
Tamer Hellou, Estefania Gauto Mariotti, Ahmed Alnughmush, Linda B Baughn, Prashant Kapoor
American Journal of Hematology. 2026-08-24

Journal Articles

Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy: Failure of the Serum Free Light Chain Ratio
Morie A Gertz, David Dingli, Miriam Hobbs, John A Lust, Ronald S Go, Amie Fonder, Yi Lin, Shaji K Kumar, Prashant Kapoor, Taxiarchis V Kourelis, S Vincent Rajkumar, Ro..., Nature
Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...
John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature

Lectures

Integration of Immunotherapy Into Treatment for Hematologic Malignancies
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

7 Advances in CAR-T Cell Therapy at Mayo ClinicSeptember 19th, 2024
COVID-19 Is Still Causing Drug Shortages That Impact Cancer CareAugust 19th, 2022
Bluebird Bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and ExpositionNovember 5th, 2020